Therapy for elderly patients with advanced nonsmall cell lung cancer

doi:10.3760/cma.j.issn.1673-422X.2018.12.012

Abstract

Abstract: Chemotherapy is recommended for stage ⅢB/Ⅳ nonsmall cell lung cancer (NSCLC) treatment. The treatments for elderly patients with advanced NSCLC are mainly singleagent chemotherapy and platinumbased combination chemotherapy. However, elderly patients tolerate chemotherapy poorly because of agerelated comorbidities. Therefore, the curative effect of elderly patients is relatively poorer as compared to their younger counterparts. Targeted therapy and immune therapy have become new research directions. It is important to select an appropriate program for elderly patients according to geriatric assessments.

Key words: Carcinoma, non-small-cell lung, Aged, Antineoplastic protocols

Zhou Jin, Wu Jie, Zhang Huibo, Chen Min. Therapy for elderly patients with advanced nonsmall cell lung cancer[J]. Journal of International Oncology, 2018, 45(12): 756-759.

References

［1］ Davidoff AJ, Tang M, Seal B, et al. Chemotherapy and survival benefit in elderly patients with advanced nonsmallcell lung cancer［J］. J Clin Oncol, 2010, 28(13): 21912197. DOI: 10.1200/JCO.2009.25.4052. ［2］ Santos FN, Cruz MR, Riera R, et al. Chemotherapy for advanced nonsmallcell lung cancer in elderly patients［J］. JAMA Oncol, 2016, 2(12): 16451646. DOI: 10.1001/jamaoncol.2016.2050. ［3］ Santos FN, de Castria TB, Cruz MR, et al. Chemotherapy for advanced nonsmall cell lung cancer in the elderly population［J］. Cochrane Database Syst Rev, 2015(10): CD010463. DOI: 10.1002/14651858.CD010463.pub2. ［4］ Gridelli C, Morabito A, Cavanna L, et al. Cisplatinbased firstline treatment of elderly patients with advanced nonsmallcell lung cancer: joint analysis of MILES3 and MILES4 Phase Ⅲ Trials［J］. J Clin Oncol, 2018, 36(25): 25852592. DOI: 10.1200/JCO.2017.76.8390. ［5］ Presley CJ, Reynolds CH, Langer CJ. Caring for the older population with advanced lung cancer［J］. Am Soc Clin Oncol Educ Book, 2017, 37: 587596. DOI: 10.14694/edbk_179850. ［6］ Gridelli C, Brodowicz T, Langer CJ, et al. Pemetrexed therapy in elderly patients with good performance status: analysis of two phase Ⅲ trials of patients with nonsquamous nonsmallcell lung cancer［J］. Clin Lung Cancer, 2012, 13(5): 340346. DOI: 10.1016/j.cllc.2011.12.002. ［7］ PazAres LG, Zimmermann A, Ciuleanu T, et al. Metaanalysis examining impact of age on overall survival with pemetrexed for the treatment of advanced nonsquamous nonsmall cell lung cancer［J］. Lung Cancer, 2017, 104: 4551. DOI: 10.1016/j.lungcan.2016.12.007. ［8］ Socinski MA, Bondarenko I, Karaseva NA, et al. Weekly nabpaclitaxel in combination with carboplatin versus solventbased paclitaxel plus carboplatin as firstline therapy in patients with advanced nonsmallcell lung cancer: final results of a phase Ⅲ trial［J］. J Clin Oncol, 2012, 30(17): 20552062. DOI: 10.1200/jco.2011.39.5848. ［9］ Reck M, Von Pawel J, Zatloukalet P, et al. Overall survival with cisplatingemcitabine and bevacizumab or placebo as firstline therapy for nonsquamous nonsmallcell lung cancer: resultsfrom a randomised phase Ⅲ trial［J］. Ann Oncol, 2010, 21(9): 18041809. DOI: 10.1093/annonc/mdq020. ［10］ Leighl NB, Zatloukal P, Mezger J, et al. Efficacy and safety of bevacizumabbased therapy in elderly patients with advanced or recurrent nonsquamous nonsmall cell lung cancer in the phase Ⅲ BO17704 study (AVAiL)［J］. J Thorac Oncol, 2010, 5(12): 19701976. DOI: 10.1097/JTO.0b013e3181f49c22. ［11］ Langer CJ, Socinski MA, Patel JD, et al. Isolating the role of bevacizumab in elderly patients with previously untreated nonsquamous nonsmall cell lung cancer: secondary analyses of the ECOG 4599 and PointBreak Trials［J］. Am J ClinOncol, 2016, 39(5): 441447. DOI: 10.1097/coc.0000000000000163. ［12］ Tian RH, Wu X, Liu X, et al. The role of angiogenesis inhibitors in the treatment of elderly patients with advanced nonsmallcell lung cancer: a metaanalysis of eleven randomized controlled trials［J］. J Cancer Res Ther, 2016, 12(2): 571575. DOI: 10.4103/09731482.151950. ［13］ Gajra A, Jatoi A. Nonsmallcell lung cancer in elderly patients: a discussion of treatment options［J］. J Clin Oncol, 2014, 32(24): 25622569. DOI: 10.1200/jco.2014.55.3099. ［14］ Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as firstline treatment for European patients with advanced EGFR mutationpositive nonsmallcell lung cancer (EURTAC): a multicentre, openlabel, randomised phase 3 trial［J］. Lancet Oncol, 2012, 13(3): 239246. DOI: 10.1016/s14702045(11)70393x. ［15］ Wu YL, Zhou C, Hu CP, et al. Afatinib versus cisplatin plus gemcitabine for firstline treatment of Asian patients with advanced nonsmallcell lung cancer harbouring EGFR mutations (LUXLung 6): an openlabel, randomised phase 3 trial［J］. Lancet Oncol, 2014, 15(2): 213222. DOI: 10.1016/s14702045(13)706041. ［16］ Tanaka H, Taima K, Tanaka Y, et al. A phase Ⅰ study of afatinib for patients aged 75 or older with advanced nonsmall cell lung cancer harboring EGFR mutations［J］. Med Oncol, 2018, 35(3): 34. DOI: 10.1007/s1203201810983. ［17］ Morikawa N, Minegishi Y, Inoue A, et al. Firstline gefitinib for elderly patients with advanced NSCLC harboring EGFR mutations. A combined analysis of NorthEast Japan Study Group studies［J］. Expert Opin Pharmacother, 2015, 16(4): 465472. DOI: 10.1517/14656566.2015.1002396. ［18］ Corre R, Gervais R, Guisier F, et al. Octogenarians with EGFRmutated nonsmall cell lung cancer treated by tyrosinekinase inhibitor: a multicentric realworld study assessing tolerance and efficacy (OCTOMUT study)［J］. Oncotarget, 2018, 9(9): 82538262. DOI: 10.18632/oncotarget.23836. ［19］ Soria JC, Ohe Y, Vansteenkiste J, et al. Osimertinib in untreated EGFRmutated advanced nonsmallcell lung cancer［J］. N Engl J Med, 2018, 378(2): 113125. DOI: 10.1056/NEJMoa1713137. ［20］ Soria JC, Tan DSW, Chiari R, et al. Firstline ceritinib versus platinumbased chemotherapy in advanced ALKrearranged nonsmallcell lung cancer (ASCEND4): a randomised, openlabel, phase 3 study［J］. Lancet, 2017, 389(10072): 917929. DOI: 10.1016/s01406736(17)30123x. ［21］ Hida T, Nokihara H, Kondo M, et al. Alectinib versus crizotinib in patients with ALKpositive nonsmallcell lung cancer (JALEX): an openlabel, randomised phase 3 trial［J］. Lancet, 2017, 390(10089): 2939. DOI: 10.1016/s01406736(17)305652. ［22］ Gandhi L, RodriguezAbreu D, Gadgeel S, et al. Pembrolizumab plus chemotherapy in metastatic nonsmallcell lung cancer［J］. N Engl J Med, 2018, 378(22): 20782092. DOI: 10.1056/NEJMoa1801005. ［23］ Hellmann MD, Ciuleanu TE, Pluzanski A, et al. Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden［J］. N Engl J Med, 2018, 378(22): 20932104. DOI: 10.1056/NEJMoa1801946. ［24］ Antonia SJ, Villegas A, Daniel D, et al. Durvalumab after chemoradiotherapy in stage Ⅲ nonsmallcell lung cancer［J］. N Engl J Med, 2017, 377(20): 19191929. DOI: 10.1056/NEJMoa1709937. ［25］ Gettinger S, Horn L, Jackman D, et al. Fiveyear followup of nivolumab in previously treated advanced nonsmallcell lung cancer: results from the CA209003 study［J］. J Clin Oncol, 2018, 36(17): 16751684. DOI: 10.1200/jco.2017.77.0412. ［26］ Hellmann MD, Rizvi NA, Goldman JW, et al. Nivolumab plus ipilimumab as firstline treatment for advanced nonsmallcell lung cancer (CheckMate 012): results of an openlabel, phase 1, multicohort study［J］. Lancet Oncol, 2017, 18(1): 3141. DOI: 10.1016/s14702045(16)306246. ［27］ AbdelWahab N, Shah M, LopezOlivo MA, et al. Use of immune checkpoint inhibitors in the treatment of patients with cancer and preexisting autoimmune disease: a systematic review［J］. Ann Intern Med, 2018, 168(2): 121130. DOI: 10.7326/m172073. ［28］ NikolichZugich J. The twilight of immunity: emerging concepts in aging of the immune system［J］. Nat Immunol, 2018, 19(1): 1019. DOI: 10.1038/s415900170006x. ［29］ Borghaei H, PazAres L, Horn L, et al. Nivolumab versus docetaxel in sdvanced nonsquamous nonsmallcell lung cancer［J］. N Engl J Med, 2015, 373(17): 16271639. DOI: 10.1056/NEJMoa1507643. ［30］ Reck M, RodriguezAbreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PDL1positive nonsmallcell lung cancer［J］. N Engl J Med, 2016, 375(19): 18231833. DOI: 10.1056/NEJMoa1606774. ［31］ Levy MH, Smith T, AlvarezPerez A, et al. Palliative care, Version 1.2014. Featured updates to the NCCN Guidelines［J］. J Natl Compr Canc Netw, 2014, 12(10): 13791388. ［32］ Temel JS, Greer JA, Muzikansky A, et al. Early palliative care for patients with metastatic nonsmallcell lung cancer［J］. N Engl J Med, 2010, 363(8): 733742. DOI: 10.1056/NEJMoa1000678. ［33］ Vergnenegre A, Hominal S, Tchalla AE, et al. Assessment of palliative care for advanced nonsmallcell lung cancer in France: a prospectiveobservational multicenter study (GFPC 0804 study)［J］. Lung Cancer, 2013, 82(2): 353357. DOI: 10.1016/j.lungcan.2013.07.014.

[1]	Wang Zihao, Wang Yu, Yang Xin, He Yi, Mo Xingkui, Yuan Tao. Research progress on the molecular mechanism and related treatments of ferroptosis in osteosarcoma [J]. Journal of International Oncology, 2024, 51(4): 239-244.
[2]	Zuo Xiaoping, Liu Xiaochuan, Wu Xiqiang, Li Zhou, Xia Tian, Liu Guofeng. Risk factors and prediction model construction of arrhythmia in elderly patients with early lung cancer after thoracoscopic pulmonary resection [J]. Journal of International Oncology, 2023, 50(12): 711-716.
[3]	Yang Sha, Yang Xiaohua, Wang Suhua, Xue Xiaoyan, Xu Jun. Analysis of risk factors for deep vein thrombosis of lower extremity after thoracoscopic surgery for elderly lung cancer and establishment and validation of prediction model [J]. Journal of International Oncology, 2022, 49(9): 532-536.
[4]	Wang Yue, Wu Qiong, Xu Yuan, Gong Wei, Xu Xiaoting. Screening and treatment progression of elderly cervical cancer [J]. Journal of International Oncology, 2022, 49(12): 754-758.
[5]	Tao Jie, Wu Mei, Zhang Yan. Efficacy and influencing factors of anlotinib in treatment of elderly patients with small cell lung cancer after second-line treatment failure [J]. Journal of International Oncology, 2022, 49(1): 39-44.
[6]	Shi Yue, Li Shen, Feng Jifeng. Treatment options for colorectal cancer primary lesions with unresectable metastases at risk of acute abdomen [J]. Journal of International Oncology, 2021, 48(11): 693-697.
[7]	Dong Fang, Xue Jincai, Wang Yunsheng, Liu Qinjiang. Progress of external beam radiotherapy for thyroid cancer [J]. Journal of International Oncology, 2019, 46(11): 641-648.
[8]	Guan Xiuwen, Ma Fei, Xu Binghe. The landscape of palliative systemic therapy and overall survival analysis of elderly patients with advanced breast cancer in China National Cancer Center [J]. Journal of International Oncology, 2019, 46(11): 657-661.
[9]	Yao Yixuan, Wang Huan, Xia Jun, Wang Jing, Sun Chao, Sun Hongli, Zhou Xin. Correlations between peripheral absolute lymphocyte count and clinicopathological characteristics of the elderly patients with multiple myeloma and its prognosis [J]. Journal of International Oncology, 2018, 45(6): 347-351.
[10]	YANG Hui, NIU Run-Gui. Analysis of prognostic factors in 162 elderly patients with inoperable locally advanced squamous cell lung cancer [J]. Journal of International Oncology, 2017, 44(5): 342-345.
[11]	Teng Fei, Cui Guimin, Shi Hongyun, Liu Miaoling, Li Yanhong. Clinical observation of radiotherapy combined with temozolomide in non-small cell lung cancer patients with brain metastases [J]. Journal of International Oncology, 2017, 44(4): 271-273.
[12]	Chen Dalei, Shen Yanyan, Lin Chuanqi, Wang Xiaohui, Shi Hao, Guo Guilong. Treatment protocols of local-regional recurrence after breast cancer surgery [J]. Journal of International Oncology, 2017, 44(12): 929-932.
[13]	ZHU Jing-Lan, CHEN Hui, LUAN Wei. Analysis of risk factors associated with postoperative lower respiratory infections in the elderly patients with lung carcinoma [J]. Journal of International Oncology, 2016, 43(2): 95-.
[14]	Li Ying, Fang Xiaomeng, Jiang Da, Dong Qian, Zhang Zengye, Zheng Fei. Meta analysis of brain metastases ideal treatment mode [J]. Journal of International Oncology, 2015, 42(2): 103-108.
[15]	YANG Li-Jiao, XU Xiang-Ying. Treatment of elderly nonsmall cell lung cancer [J]. Journal of International Oncology, 2014, 41(6): 429-432.